title: Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
abstract: A 64-year-old female who has undergone D2 total gastrectomy was started on adjuvant treatment with TS-1. Four weeks after initiation of TS-1, the patient developed a rare complication of life-threatening toxic epidermal necrolysis. TS-1 was discontinued and the patient received treatment with intravenous immunoglobulin and supportive care with resolution of toxic epidermal necrolysis. TS-1 has been used for the treatment of gastric cancer, both in the adjuvant and metastatic setting, and is increasingly being used in other malignancies such as colon, pancreatic and non-small cell lung cancer. TS-1 is generally well tolerated. To our knowledge, this is the first reported case of toxic epidermal necrolysis associated with the usage of TS-1.
authors.affiliation: Department of Haematology-Oncology, National University Cancer Institute (NCIS), National University Health System, Level 7, Tower Block, 1E, Kent Ridge Road, Singapore 119228, Singapore.
authors.forename: Chee Seng
authors.initials: CS
authors.lastname: Tan
authors.forename: Robert
authors.initials: R
authors.lastname: Lim
authors.forename: Thiam Chye
authors.initials: TC
authors.lastname: Lim
authors.forename: Chen Wee
authors.initials: CW
authors.lastname: Aw
authors.forename: Sze Wei
authors.initials: SW
authors.lastname: Yeo
authors.forename: Soo-Chin
authors.initials: SC
authors.lastname: Lee
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D010166:Palliative Care; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013280:Stomatitis / Q000139:chemically induced*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D016756:Immunoglobulins, Intravenous; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid